The Relationship Between Prostate Biopsy Results and PSA and Free PSA Ratio Changes in Elevated Serum PSA Patients with and without Antibiotherapy.
Prostate Cancer
Prostate specific antigen
benign prostatic hyperplasia
empiric antibiotic treatment
prostate biopsy
Journal
Asian Pacific journal of cancer prevention : APJCP
ISSN: 2476-762X
Titre abrégé: Asian Pac J Cancer Prev
Pays: Thailand
ID NLM: 101130625
Informations de publication
Date de publication:
01 Apr 2020
01 Apr 2020
Historique:
received:
19
11
2019
entrez:
26
4
2020
pubmed:
27
4
2020
medline:
3
2
2021
Statut:
epublish
Résumé
To evaluate the impact of antibiotic treatment on total prostate specific antigen (PSA) levels and free/total (f/t) PSA ratio and the relevance of these changes to prostate biopsy results. We retrospectively evaluated 1,062 patients with elevated age-adjusted serum PSA levels who underwent prostate biopsy between 2004 and 2016. A total of 303 cases with followup PSA levels and f/t PSA ratio before and after antibiotherapy were included into this study. There were 214 patients with persistent elevated serum PSA levels after antibiotic treatment followed by prostate biopsy (treatment group) and 89 patients who had prostate biopsy after a mean followup of 1 month without antibiotherapy (control group). The groups were compared with regard to both 5% and 10% cut off changes in serum PSA levels and f/t PSA ratios. Antibiotic treatment had no impact on the relation between serum PSA levels and biopsy results at both cut off values. On the other hand, f/t PSA ratio changes at both cut off values with relevance to antibiotic treatment were found to be related with histopathologic results. While increase in f/t PSA ratio was more related with benign biopsies, decrease in f/t PSA ratio was more related with cancer (for 5% cut off value p= 0.014, p= 0.004; for 10% cut off value p= 0.026, p= 0.014). Changes at f/t PSA ratio rather than total PSA only, particularly in antibiotic treated cases appear to be more useful in decision making for biopsy.
Identifiants
pubmed: 32334469
doi: 10.31557/APJCP.2020.21.4.1051
pmc: PMC7445968
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1051-1056Références
Urol Int. 2006;76(1):20-6
pubmed: 16401916
Int J Clin Exp Med. 2014 Aug 15;7(8):2230-5
pubmed: 25232413
Actas Urol Esp. 2012 Apr;36(4):234-8
pubmed: 22258038
BJU Int. 2013 Nov;112(7):925-9
pubmed: 23890317
JAMA. 2003 May 28;289(20):2695-700
pubmed: 12771116
Nat Clin Pract Urol. 2007 Jan;4(1):1
pubmed: 17211413
Prostate Cancer Prostatic Dis. 2008;11(2):148-52
pubmed: 17637759
Urology. 2016 Apr;90:32-7
pubmed: 26802800
BJU Int. 2011 May;107(10):1576-81
pubmed: 21244610
Int J Biol Markers. 2002 Apr-Jun;17(2):84-9
pubmed: 12113586
Prostate Cancer Prostatic Dis. 2006;9(3):235-8
pubmed: 16718277
Minerva Urol Nefrol. 2016 Jun;68(3):270-4
pubmed: 25014678
Int Braz J Urol. 2009 Sep-Oct;35(5):551-5; discussion 555-8
pubmed: 19860933
Urol Int. 2008;80(2):186-92
pubmed: 18362491
J Endourol. 2013 Aug;27(8):1061-7
pubmed: 23641793
J Med Liban. 2002 Jan-Apr;50(1-2):23-5
pubmed: 12841309
J Urol. 2010 Mar;183(3):940-4
pubmed: 20089269
Int Urol Nephrol. 2010 Mar;42(1):13-8
pubmed: 19548108
Arch Ital Urol Androl. 2004 Dec;76(4):154-8
pubmed: 15693428
J Urol. 2005 Jul;174(1):161-4
pubmed: 15947609
Urol Int. 2009;82(3):266-9
pubmed: 19440011
Urol Oncol. 2015 May;33(5):201.e17-24
pubmed: 25752230
Arch Ital Urol Androl. 2014 Sep 30;86(3):202-4
pubmed: 25308584
Urol Int. 2011;87(4):416-9
pubmed: 21934292
Radiology. 2014 May;271(2):435-44
pubmed: 24484061
Int Neurourol J. 2010 Aug;14(2):100-4
pubmed: 21120219
Urology. 2008 Dec;72(6 Suppl):S12-24
pubmed: 19095124
J Urol. 2009 Jan;181(1):128-32
pubmed: 19012907